Clinical Trial Update: A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial assessing paclitaxel with or without ramucirumab in gastric or gastroesophageal junction adenocarcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 3 | Status: COMPLETED | Results posted: 2021-08-03